Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences

Published on :

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that it will be hosting an R&D Day Event and participating in upcoming scientific conferences. Please see additional details below:

Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell Therapy Manufacturing

Orgenesis Logo
Published on :

Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and The Johns Hopkins University, today announce the next phase of their collaboration. This new phase involves construction of a cell and gene therapy processing facility for point of care treatment of patients at Johns Hopkins which is planned to start in Q2 2022 and is expected to be operational in Q2 of 2023.

TEDCO 2021 Recap – Successful Initiatives and New Funding Programs

TEDCO logo over a backdrop of the Maryland flag
Published on :

2021 was a phenomenal year for TEDCO (Maryland Technology Development Corporation)! Despite challenges and setbacks due to COVID-19, the venture and equity investment organization pushed boundaries and made phenomenal strides in growth and expansion across the state of Maryland. TEDCO also provided crucial funding, resources, and networking opportunities for entrepreneurs and startups in the state.

Avidea Merger with Vaccitech Provides New Opportunities for SNAPvax Platform

Image with the Avidea and Vaccitech logos with an image of Avidea's SNAPvax technology
Published on :

Privately-held Avidea is developing next-generation T cell immunotherapies for the treatment of cancer and autoimmune diseases. The company’s immunotherapies are driven by its polymer-drug conjugate technology platform, SNAPvax, which is designed to co-deliver multiple antigens and immunomodulators in nanoparticles of precise, programmable size and composition. This is done so in order to enable the development of immunotherapy product candidates with tighter control over immune responses. The SNAPvax platform is designed to induce high magnitude cytotoxic T cells for treating cancer and chronic infections. It can also be configured to induce regulatory T cells for treating autoimmunity and allergies.

McBee, Moore & Vanik IP: Intellectual Property Law Firm Celebrates Six Years

Published on :

McBee, Moore & Vanik IP, LLC began in 2016 when partners Susan McBee, C.G. Moore, David Vanik and 12 employees came together to form a new patent law firm with improved client service as the ultimate goal. This year, the firm is celebrating six years together. 

Erica Kimmel and Nina Manguiri Join Gilbane Building Company to Expand Business Development in Maryland

Photo of Erica Kimmel and Nina Manguiri
Published on :

Gilbane Building Company is pleased to announce the addition of Erica Kimmel and Nina Manguiri as Business Development Managers in the Baltimore, MD office. Together they bring over 39 years of strategic sales experience.  Working alongside Greg Permison, who joined Gilbane in 2018, they will support Gilbane’s business development effort for continued growth and expansion in the Maryland market.

5 Tips for PhD Students and Postdocs to Help Land that Non-Academic Job

Photo of people sitting at a table on their laptops
Published on :

As years went by, I started to realize that there was a whole world of opportunities for PhDs beyond the bench – careers that were just as intellectually stimulating and still scratched that scientific itch without ever having to pick up a pipette. However, the road to reach these careers was a bit foggier compared to academia. Did I need to do a postdoc? How important are publications? How do I make myself stand out?

Ezekiel Kelley Joins Workforce Genetics as Director of Operations and Workforce Development Solutions

Headshot of Ezekiel Kelley
Published on :

Workforce Genetics welcomes Ezekiel Kelley as the new Director of Operations and Workforce Development Solutions. Ezekiel will establish and implement efficient operating systems to drive growth across the whole organization – including the Recruiting and BioBuzz divisions. Additionally, he will be the head architect for building innovative new workforce solutions; including a new online community and talent marketplace that seeks to expand access to virtual workforce development and education tools, increase career mobility, and democratize access to rewarding life science careers.